Merck Frosst Newsroom

Welcome to the Merck Frosst Newsroom

This site is designed to provide journalists with quick and easy access to recent information about Merck Frosst. Please click on a category below to view news releases, b-rolls, photos and fact sheets.

For Merck financial news, please visit www.merck.com.
To view the media contact list, click here.

Corporate News

July 8, 2010	Merck Details Plans to Restructure Merck Frosst as Part of a Global Initiative to Integrate Worldwide Operations, Following the Merger of Merck and Schering-Plough
June 4, 2010	Merck Announces Launch of Pioneering Collaborative Cancer Trials Network at 2010 American Society of Clinical Oncology Meeting
May 14, 2010	Merck and Cardiome Announce Phase III Study Results Comparing Investigational Compound Vernakalant Intravenous to Amiodarone Injection in Conversion of Atrial Fibrillation to Normal Sinus Rhythm
May 11, 2010	Merck Highlights Robust Late-Stage Pipeline, Global Business Strategy and Progress of Integration
May 11, 2010	Merck Positioned to Drive Growth Through Innovative Portfolio, Pipeline and Strategy for Growth in Emerging Markets
Apr 15, 2010	Merck partners with Ontario in support of cancer research at Princess Margaret Hospital
Apr 15, 2010	Merck is Proud to Support Budding Young Scientists in Quebec
Mar 2, 2010	Merck - Teaming Up With Young People in Their Scientific Adventure
Feb 5, 2010	Merck Supporting Relief Efforts in Haiti
Feb 4, 2010	Merck Partners with BC Centre for Excellence in HIV/AIDS for Seek and Treat research program to reduce HIV/AIDS incidence in BC
Feb 3, 2010	Sport, Peace and Development: How Can Sport Contribute to Positive Social Change?
Feb 2, 2010	Merck Celebrates 50 Years of Science Fairs in Quebec
Jan 21, 2010	Merck Supporting Relief Efforts in Haiti
Nov 4, 2009	New Merck Begins Operations Worldwide
Nov 3, 2009	Merck and Schering-Plough to Complete Merger Today
Oct 8, 2009	Quebec Government Supports a Strong Biopharmaceutical Sector
Aug 3, 2009	Sanofi-Aventis To Acquire Merck's Interest In Merial
May 11, 2009	Ontario Court Grants Merck Time to Appeal Class Certification of Vioxx Action
Apr 8, 2009	Merck & Co., Inc. and Cardiome Sign License Agreement for Vernakalant, an Investigational Drug for Treatment of Atrial Fibrillation
Mar 30, 2009	Merck to Seek Appellate Review of Class Certification Decision in VIOXX® Proceedings in Ontario
Mar 09, 2009	MERCK AND SCHERING-PLOUGH TO MERGE
	MORE

Product News

Aug 17, 2010	Alberta, New Brunswick, Nova Scotia and NIHB (Non-Insured Health Benefits Program) lead the way with the listing of SIMPONI™ for three rheumatic conditions
Jul 21, 2010	NACI Strengthens Recommendations on Rotavirus Vaccination
May 26, 2010	More women can prevent chemotherapy-induced nausea and vomiting
Feb 23, 2010	Gardasil^® Approved by Health Canada for Males to Prevent Genital Warts
Feb 17, 2010	Gardasil^® Helps Prevent Anal Cancer in Men, Showed New Study
Nov 17, 2009	Cancidas^® is Now Available for Pediatric Patients
Oct 22, 2009	Data Presented at the International Diabetes Federation World Congress Compares JANUMET™ (sitagliptin/metformin HCl) to Metformin Alone as Initial Therapy
Oct 20, 2009	Canada Approves Isentress^® For Adults Starting HIV Treatment
Oct 13, 2009	New Type 2 Diabetes Tablet Offers Powerful Blood Glucose Control Without Weight Gain
Sep 22, 2009	Merck Frosst's Zostavax™ Now Available In Canada
Sep 15, 2009	New Treatment Zolinza™ Reduces Visible Impact Of Advanced Form Of Skin Lymphoma
Jul 20, 2009	Raltegravir as Effective as Efavirenz at Suppressing HIV Viral Load and Increasing CD4 Cell Counts in Treatment-Naïve Patients Up to 144 Weeks When Used in Combination Therapy
Jul 9, 2009	Merck Frosst Statement in Response to the Health Canada July 2009 edition of the Canadian Adverse Reaction Newsletter (CARN) on SINGULAIR^® (montelukast)
Jun 25, 2009	New study shows EMEND^® significantly improved prevention of chemotherapy-induced nausea and vomiting, when added to standard therapy
May 8, 2009	Study shows HPV-16 Vaccine Demonstrated more than 8 Years of Protection Against Disease
Feb 11, 2009	Raltegravir, in Combination with Other HIV Medicines Shown as Effective as Efavirenz in Suppressing Viral Load and Increasing CD4 Cell Counts in Treatment-Naïve HIV-infected Patients with High Levels of Virus, Across Various Populations, in Investigational Study Phase III Studies Showed Raltegravir in Combination Therapy Provided Significant Viral Load Reductions through 96 Weeks in Treatment-Experienced Patients with Triple-Class Resistant HIV
Feb 11, 2009	Data from Raltegravir in Patients Whose HIV is Controlled on a Lopinavir/Ritonavir-Based Therapy Presented at the 16th Conference on Retroviruses and Opportunistic Infections -Switching from Lopinavir/Ritonavir-Based to Raltegravir-Based Combination Antiretroviral Therapy Significantly Improved Total Cholesterol, Triglycerides, Non-HDL-Cholesterol at Week 12 -Switching from Lopinavir/Ritonavir-Based to Raltegravir-Based Combination Antiretroviral Therapy Did Not Demonstrate Non-Inferior Virologic Efficacy
	MORE